Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.37 |
| ▸ | DPP4 known ✓ | P27487 | 4/20 | 0.37 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248269 | 0.99 | ALDH1A1 (0.42) | ALDH1A1GAAPDK1PDK2PDK3 | |
| SCHEMBL1248268 | 0.99 | ALDH1A1 (0.42) | ALDH1A1GAAPDK1PDK2PDK3 | |
| SCHEMBL1248266 | 0.99 | ALDH1A1 (0.42) | ALDH1A1GAAPDK1PDK2PDK3 | |
| Hydrochloric Acid SCHEMBL16611804 | 0.90 | FKBP1A (0.41) | ALDH1A1GAAPDK1PDK2PDK3 | |
| Hydrochloric Acid SCHEMBL16611802 | 0.90 | FKBP1A (0.41) | ALDH1A1GAAPDK1PDK2PDK3 | |
| SCHEMBL16611571 | 0.89 | FKBP1A (0.41) | ALDH1A1GAAPDK1PDK2PDK3 | |
| SCHEMBL16611573 | 0.89 | FKBP1A (0.41) | ALDH1A1GAAPDK1PDK2PDK3 | |
| SCHEMBL3666219 | 0.89 | AGTR2 (0.43) | ALDH1A1GAAPDK1PDK2PDK3 | |
| SCHEMBL9949645 | 0.86 | FKBP1A (0.39) | ALDH1A1GAAPDK1PDK2PDK3 | |
| SCHEMBL9949649 | 0.86 | FKBP1A (0.39) | ALDH1A1GAAPDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348578-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2022-11-03 | — | — | US | disclosed |
| EP-3299370-B1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-11-24 | — | — | EP | disclosed |
| EP-3067355-B1 | CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE | MEIJI SEIKA PHARMA CO LTD (JP) | 2020-12-16 | — | — | EP | disclosed |
| US-20200181143-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-10604522-B2 | Processes for producing diazabicyclooctane compounds | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| EP-3613740-A1 | PREPARATION OF A DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3613741-A1 | PREPARATION OF A DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-20190031659-A1 | PROCESSES FOR PRODUCING DIAZABICYCLOOCTANE COMPOUNDS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000492-B2 | Process for producing diazabicyclooctane derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-3299370-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20170283415-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-10-05 | — | — | US | disclosed |
| US-20160264573-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3067355-A1 | CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-3050883-A1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2016-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348578-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | CCNA1, RCC1, DDT | GAA 2839/4885ACE 1597/4885DPP4 139/4885 |
| US-10000492-B2 | Process for producing diazabicyclooctane derivative | OGFOD1, HAAO, CLCN2 | GAA 3646/4885ACE 3367/4885DPP4 1887/4885 |
| US-20170283415-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE | OGFOD1, HAAO, CLCN2 | GAA 3646/4885ACE 3367/4885DPP4 1887/4885 |
| US-10604522-B2 | Processes for producing diazabicyclooctane compounds | DHCR7, C9, CYCS | GAA 3095/4885ACE 2400/4885DPP4 2395/4885 |
| US-20190031659-A1 | PROCESSES FOR PRODUCING DIAZABICYCLOOCTANE COMPOUNDS | DHCR7, C9, CYCS | GAA 3095/4885ACE 2400/4885DPP4 2395/4885 |
| US-20200181143-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | CCNA1, RCC1, DDT | GAA 2839/4885ACE 1597/4885DPP4 139/4885 |
| US-20160264573-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | CLCN2, ODC1, KCNN4 | GAA 3868/4885ACE 4334/4885DPP4 554/4885 |
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | CLCN2, ODC1, KCNN4 | GAA 3868/4885ACE 4334/4885DPP4 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.